Shares of Aurobindo Pharma dipped 5 per cent at Rs 781 on the BSE in the intra-day trade on Friday after the company reported a disappointing operational performance in June 2021 quarter (Q1FY22), amid decline across US market & antiretroviral (ARVs).
In Q1FY22, the company’s profit after tax (PAT) was down 1.7 per cent year on year (YoY) and 4 per cent quarter on quarter (QoQ) at Rs 770 crore. It was, however, in-line with analysts' estimate on higher than expected other income and a lower tax rate. Revenue, meanwhile, de-grew 3.8 per cent YoY and 5.0 per cent
In Q1FY22, the company’s profit after tax (PAT) was down 1.7 per cent year on year (YoY) and 4 per cent quarter on quarter (QoQ) at Rs 770 crore. It was, however, in-line with analysts' estimate on higher than expected other income and a lower tax rate. Revenue, meanwhile, de-grew 3.8 per cent YoY and 5.0 per cent